BiotechTube

Enoxaparine

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hemodialysis

Conditions

Hemodialysis

Trial Timeline

May 1, 2006 → Jun 1, 2007

NCT ID
NCT00347490

About Enoxaparine

Enoxaparine is a approved stage product being developed by Sanofi for Hemodialysis. The current trial status is completed. This product is registered under clinical trial identifier NCT00347490. Target conditions include Hemodialysis.

What happened to similar drugs?

1 of 15 similar drugs in Hemodialysis were approved

Approved (1) Terminated (0) Active (14)
🔄R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
🔄R744 + R744Chugai PharmaceuticalPhase 3
🔄R744Chugai PharmaceuticalPhase 3
🔄roxadustatAstellas PharmaPhase 3
🔄roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
🔄roxadustatAstellas PharmaPhase 3
✅DoravirineMerckApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00347490ApprovedCompleted

Competing Products

20 competing products in Hemodialysis

See all competitors
ProductCompanyStageHype Score
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
40
R744 + R744Chugai PharmaceuticalPhase 3
40
R744Chugai PharmaceuticalPhase 3
40
roxadustatAstellas PharmaPhase 3
40
ASP7991Astellas PharmaPhase 1
29
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
ASP1585Astellas PharmaPhase 2
35
Kiklin capsulesAstellas PharmaPre-clinical
26
DoravirineMerckApproved
43
BPS804 + PlaceboNovartisPhase 2
27
PA21 + Sevelamer hydrochlorideKissei PharmaceuticalPhase 3
40
PA21 + PA21 + PA21 + PA21 + PlaceboKissei PharmaceuticalPhase 2
35
PA21Kissei PharmaceuticalPhase 3
40
PA21Kissei PharmaceuticalPhase 3
40
[¹⁴C]EtelcalcetideAmgenPhase 1
29
Epoetin HospiraPfizerPhase 3
40
Epoetin HospiraPfizerPhase 3
40
sodium thiosulfateSanofiPre-clinical
26
Alirocumab 150 MG/ML [Praluent]Regeneron PharmaceuticalsPhase 3
36